Vivalis and Intercell have agreed to the terms of a merger to create a new European biotechnology company called Valneva that will specialize in vaccines and antibodies. Vivalis and Intercell have ...

* BioDiem confirms successful and abundant growth of its virus in VIVALIS' proprietary EB66(®) cell line in Stage 1 of its collaboration with VIVALIS. * The next stage of the project will use known ...

PARIS, Nov 24 (Reuters) - French biotech firm Vivalis and British partner GlaxoSmithKline have won U.S. clearance to begin testing on humans for the first time flu vaccines which were produced using ...

Valneva SE (Valneva) has announced the completion of the merger of equals between Vivalis and Intercell, creating a new European biotech company focusing on vaccines and antibodies, striving to become ...

Vivalis shareholders will own 55% of Valneva, with Intercell’s shares being converted at a 39% premium to the pre-deal share prices. An extra 8.6m shares will be issued to former Intercell ...

LONDON/PARIS (Reuters) - France's Vivalis and Austrian vaccine specialist Intercell are linking up in a rare cross-border deal that shows the need for Europe's fledgling biotech companies to grow in ...

Firm is developing VLP-based vaccines. Vivalis has granted Novavax the right to use its EB66® cell line for the production of VLP-based vaccines against several new potential viruses. The EB66 cell ...

Companies will collaborate on antibody discovery against multiple targets. Vaccines company Sanofi Pasteur is paying Vivalis €3 million up front for exclusive access to the latter’s Humalex® platform ...

The Singapore Immunology Network (SIgN), an institute of the Agency of Science, Technology and Research (A*STAR), and VIVALIS, a French biopharmaceutical company, announced today the discovery of two ...

Novavax and Vivalis announced the completion of a research license to use the Vivalis proprietary EB66 cell line, for the production of Novavax VLP based vaccines. Through this collaboration, Novavax ...

NANTES, FRANCE--(Marketwire - June 8, 2010) - VIVALIS (NYSE Euronext: VLS) announced today the signature with Sanofi Pasteur, the vaccines division of sanofi-aventis Group (Euronext: SAN and NYSE: SNY ...